Collegium Medicum, Jagiellonian University, Medyczna 9, PL 30-688 Kraków, Poland.
Pharmacol Rep. 2009 Nov-Dec;61(6):1184-91. doi: 10.1016/s1734-1140(09)70182-3.
Preclinical data indicate the involvement of glutamatergic and serotonergic pathways in the antidepressant activity of zinc. The present study investigated alterations in N-methyl-D-aspartate (NMDA)/glutamatergic and serotonergic receptors (using radioligand binding) induced by chronic treatment (14-day) with zinc hydroaspartate (65 mg/kg). Moreover, the mRNA and protein levels of brain-derived neurotrophic factor (BDNF) were also assessed. Chronic zinc administration reduced the affinity of glycine to glycine/NMDA receptors in the rat frontal cortex and increased the density of 5-HT(1A) and 5-HT(2A) serotonin receptors in the hippocampus and frontal cortex, respectively. These receptor alterations may be in part due to increased BDNF mRNA and protein levels in the rat frontal cortex. These results indicate that chronic zinc treatment alters glutamatergic and serotonergic systems, which is a hallmark of clinically effective antidepressants.
临床前数据表明,谷氨酸能和 5-羟色胺能途径参与了锌的抗抑郁作用。本研究探讨了慢性(14 天)给予锌水合天冬氨酸(65mg/kg)后 NMDA/谷氨酸能和 5-羟色胺能受体(使用放射性配体结合)的变化。此外,还评估了脑源性神经营养因子(BDNF)的 mRNA 和蛋白水平。慢性锌给药降低了大鼠前额皮质中甘氨酸对甘氨酸/NMDA 受体的亲和力,并分别增加了海马和前额皮质中 5-HT1A 和 5-HT2A 血清素受体的密度。这些受体的改变部分可能是由于大鼠前额皮质中 BDNF mRNA 和蛋白水平的增加。这些结果表明,慢性锌治疗改变了谷氨酸能和 5-羟色胺能系统,这是临床有效抗抑郁药的标志。